Omnicell (OMCL) Tops Q3 EPS by 5c; Lowers Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Omnicell Announces Financial Results for Third Quarter 2022
November 2, 2022 8:01 AM EDTGAAP and non-GAAP revenues of $348 million
GAAP net income per diluted share of $0.37
Non-GAAP net income per diluted share of $1.00
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ: OMCL) (Omnicell, we, our, us, management, or the Company), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its third quarter ended September 30, 2022 and updated 2022 guidance.
Randall Lipps, Chairman, President, Chief Executive Officer, and Founder of Omnicell, said, In the third quarter, we... More
